[Influence of arteriovenous hemofiltration on teicoplanin pharmacokinetics].
OBJECTIVE
To assess the pharmacokinetics of a single dose of teicoplanin in critically ill patients treated with continuous arteriovenous haemofiltration (CAVH).


METHODS
Prospective open clinical study.


METHODS
Eleven patients with acute renal insufficiency and suspected of a Gram negative infection.


METHODS
After injection of teicoplanin, 6 mg.kg-1 over 30 minutes the plasma and haemofiltrate concentrations were measured over 24 hours with high power liquid chromatography (HPLC).


RESULTS
In plasma, the mean half-life of the first phase was 0.6 +/- 0.2 hour and terminal half-life was 16.4 +/- 5 8 hours, total clearance 30.4 +/- 7.1 mL.h-1.kg-1, volume of distribution was 0.7 +/- 0.3 L.kg-1 and the mean resident time 19.2 +/- 7.4 hours. In the haemofiltrate, the amount of teicoplanin eliminated after 24 hours was less than 1% in seven patients, between 1.8 and 3.7% in three and reached 7% in one patient.


CONCLUSIONS
During CAVH, the elimination of a single dose of teicoplanin in the haemofiltrate is low.
Choufane
S
S
Service d'anesthésie-réanimation, CHU Saint-Louis, Paris, France.
Lobjoie
E
E
Tinturier
F
F
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D003422:Critical Care; D006440:Hemofiltration; D006801:Humans; D011446:Prospective Studies; D051437:Renal Insufficiency; D017334:Teicoplanin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D017334:Teicoplanin
Influence de l'hémofiltration artérioveineuse sur l'elimination de la teicoplanine.